$23.01
0.582.59%
마지막 업데이트: Oct 22, 7:51 AM
$22.79
0.361.6%
Benzinga
Benzinga
Benzinga
목요일, 10월 22
Benzinga
© 2026 Benzinga | All Rights Reserved
Viridian Therapeutics (VRDN) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-1.02 | $-1.07 | $-0.96 | $-0.89 |
| Actual | $-1.05 | $-0.90 | $-1.08 | $-0.34 |
| Surprise | -2.94% | +15.9% | -12.5% | +61.8% |
| Revenue | ||||
| Estimate | $22000 | $27750 | $16.8M | $25.7M |
| Actual | $233000 | $141000 | $132000 | $70570 |
| Surprise | +959.1% | +408.1% | -99.2% | -99.7% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-1.04 | $-0.95 | $-0.73 | $-0.59 |
| Revenue | ||||
| Consensus | $4.9M | $19.3M | — | — |
| 회계 분기 | 보고된 날짜 | 실제 EPS | 예상 EPS | 놀라다 % |
|---|---|---|---|---|
| Q2 | Aug 6, 2026 | $-1.05 | $-1.02 | -2.94 % |
| Q1 | May 5, 2026 | $-0.90 | $-1.07 | 15.9 % |
| Q4 | Feb 26, 2026 | $-1.08 | $-0.96 | -12.5 % |
| Q3 | Nov 5, 2025 | $-0.34 | $-0.89 | 61.8 % |
| 회계 분기 | 보고된 날짜 | 실제 수익 | 예상 수익 | 놀라다 % |
|---|---|---|---|---|
| Q2 | Aug 6, 2026 | $233.00K | $22.00K | 959.1 % |
| Q1 | May 5, 2026 | $141.00K | $27.75K | 408.1 % |
| Q4 | Feb 26, 2026 | $132.00K | $16.84M | -99.2 % |
| Q3 | Nov 5, 2025 | $70.57K | $25.74M | -99.7 % |